Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression

Khan, Arifa,b; Sambunaris, Angeloc; Edwards, Johnd; Ruth, Adame; Robinson, Donald S.f

International Clinical Psychopharmacology: March 2014 - Volume 29 - Issue 2 - p 86–92
doi: 10.1097/YIC.0000000000000016
Original Articles

Vilazodone is a potent selective serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder in adults. To assess the efficacy of vilazodone across a range of symptoms and severities of depression, data from two phase III, 8-week, randomized, double-blind, placebo-controlled trials were pooled for analysis. Overall improvement in depressive symptoms measured using the Montgomery–Åsberg Depression Rating Scale (MADRS) and the 17-item Hamilton Depression Rating Scale was statistically significant (P<0.05) for vilazodone treatment compared with placebo as early as Week 1 and continued throughout double-blind treatment. Vilazodone treatment compared with placebo showed significant improvement on all 10 individual MADRS symptom items at end of treatment (P<0.01). Rates of response and remission were significantly greater in the vilazodone group relative to the placebo group, with numbers needed to treat ranging from eight to nine for response and 12–17 for remission. Between-group treatment differences in MADRS and the other outcome measures were similar among all depression subgroups, with no consistent pattern associated with depression severity. These findings support the efficacy of vilazodone across a broad range of depressive symptoms and severities for the treatment of major depressive disorder.

aNorthwest Clinical Research Center, Bellevue, Washington

bDepartment of Psychiatry, Duke University School of Medicine, Durham, North Carolina

cAtlanta Institute of Medicine & Research, Atlanta, Georgia

dForest Research Institute, Jersey City, New Jersey

ePrescott Medical Communications Group, Chicago, Illinois

fWorldwide Drug Development, Shelburne, Vermont, USA

Correspondence to Arif Khan, Northwest Clinical Research Center, 1900 116th Avenue NE #112, Bellevue, WA 98004, USA Tel: +1 425 453 0404; fax: +1 425 453 1033; e-mail:

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Received June 24, 2013

Accepted September 26, 2013

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.